[
  {
    "ts": null,
    "headline": "FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention",
    "summary": "GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.",
    "url": "https://finnhub.io/api/news?id=edee4b47e69a9355686e8c580418956c2399e9d1e4b8e7e1f7bbb6bb0d2224d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750354200,
      "headline": "FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention",
      "id": 135399189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.",
      "url": "https://finnhub.io/api/news?id=edee4b47e69a9355686e8c580418956c2399e9d1e4b8e7e1f7bbb6bb0d2224d4"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option",
    "summary": "Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first twice-yearly PrEP option in the U.S., supported by strong Phase 3 data. Although the company reported a return to profitability in its latest earnings, the stock's price movement was flat over the last quarter, aligning with the broader market's 9.9% annual uptick. This approval, along with positive clinical trial results for other treatments, would have added weight...",
    "url": "https://finnhub.io/api/news?id=5a689d0bae0c2ce5e3ac118352f896f02ffe77245b21db2b6f59a648a43e4b05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750353514,
      "headline": "Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option",
      "id": 135413527,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first twice-yearly PrEP option in the U.S., supported by strong Phase 3 data. Although the company reported a return to profitability in its latest earnings, the stock's price movement was flat over the last quarter, aligning with the broader market's 9.9% annual uptick. This approval, along with positive clinical trial results for other treatments, would have added weight...",
      "url": "https://finnhub.io/api/news?id=5a689d0bae0c2ce5e3ac118352f896f02ffe77245b21db2b6f59a648a43e4b05"
    }
  },
  {
    "ts": null,
    "headline": "Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=a7b5ae5312f3cc9a0be6fe09ddf2aef8eb9b204520525d8eac6fe77629749ae0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750341009,
      "headline": "Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term",
      "id": 135396962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=a7b5ae5312f3cc9a0be6fe09ddf2aef8eb9b204520525d8eac6fe77629749ae0"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences’ Yeztugo receives approval from US FDA for HIV",
    "summary": "The FDA approval was based on the outcomes from Phase III PURPOSE I and II trials.",
    "url": "https://finnhub.io/api/news?id=3b3926d1934df6f5a3035d0d794fc3e5f11be41e7270fff411d2efe528775685",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750325066,
      "headline": "Gilead Sciences’ Yeztugo receives approval from US FDA for HIV",
      "id": 135396963,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The FDA approval was based on the outcomes from Phase III PURPOSE I and II trials.",
      "url": "https://finnhub.io/api/news?id=3b3926d1934df6f5a3035d0d794fc3e5f11be41e7270fff411d2efe528775685"
    }
  },
  {
    "ts": null,
    "headline": "Celltrion opens new UK headquarters in Uxbridge, UK",
    "summary": "LONDON, June 19, 2025--Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company’s dedication to long-term growth and partnership in the UK market.",
    "url": "https://finnhub.io/api/news?id=d1f6e939eca9d2a8bd2e36883073c0a9d9da3c9d1a11a02bb608cac50a78f4ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750301340,
      "headline": "Celltrion opens new UK headquarters in Uxbridge, UK",
      "id": 135376358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "LONDON, June 19, 2025--Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company’s dedication to long-term growth and partnership in the UK market.",
      "url": "https://finnhub.io/api/news?id=d1f6e939eca9d2a8bd2e36883073c0a9d9da3c9d1a11a02bb608cac50a78f4ed"
    }
  }
]